• Revenue up 3.8% to $3.64M
• Loss reduced by 39.3% to $686,754
• Operating cash outflow improved by $748K to $473K

Global Health Limited reported its financial results for the half-year ended 31 December 2024. Revenue from ordinary activities increased by 3.8% to $3.64M, while the consolidated loss of the Group reduced by 39.29% to $686,754 compared to the previous corresponding period. The steady increase in revenue combined with a 3% reduction in total expenses resulted in a $592K (55%) improvement in EBITDA, moving from a loss before interest, taxes, depreciation and amortisation of $1.072M in the previous corresponding period to a loss of $480K. Research and development expenses reduced by $359K (24%) to $1.11M, representing 22% of total expenses compared to 28% in the previous corresponding period. Operating cashflows improved by $748K, moving from an operating cash outflow of $1.221M in the previous corresponding period to an operating cash outflow of $473K. The company raised $350K through the issue of convertible notes and repaid $136K of debt, resulting in a net financing cash inflow of $214K. The closing cash balance as at 31 December 2024 was $1.813M.